Connect with us

Technology

HEAG Launches Innovative AI Tool to Assist Financial Aid Professionals

Published

on

Designed for HEAG’s consulting staff, ReggieAI will provide quick, accurate, and detailed answers to specific Title IV Financial Aid processing questions that will streamline the Title IV compliance process and significantly benefit our college and university clients.

WELLESLEY, Mass., Dec. 16, 2024 /PRNewswire-PRWeb/ — The Higher Education Assistance Group (HEAG), a leader in Title IV Financial Aid consulting and outsourcing, is thrilled to announce the launch of its groundbreaking new AI tool, ReggieAI. Designed for our consulting staff, ReggieAI will provide quick, accurate, and detailed answers to specific Title IV Financial Aid processing questions that will streamline the Title IV compliance process and significantly benefit our college and university clients.

“Our AI Chatbot, Reggie AI, provides our consultants with instantaneous answers to difficult questions, significantly reducing the time it takes to respond to student inquiries or handle a processing request.”

 This robust, cutting-edge technology promises to save HEAG consultants valuable time in finding the answers to complex Title IV regulatory questions. ReggieAI leverages advanced artificial intelligence to search industry specific information, including regulatory policies and procedures, student eligibility requirements, and federal loan processing questions. With its innovative capabilities, the tool is set to redefine the Title IV Financial Aid consulting industry.

“Navigating the various available resources to obtain answers to Title IV regulatory and compliance questions is time consuming and can cause delays for students who need to secure federal funds to attend college,” said Milton Kerstein, President of the Higher Education Assistance Group. “Our AI Chatbot, Reggie AI, provides our consultants with instantaneous answers to difficult questions, significantly reducing the time it takes to respond to student inquiries or handle a processing request, thereby streamlining the Title IV process and improving the overall financial aid experience for students and families.”

About HEAG

The launch of ReggieAI aligns with HEAG’s commitment to quality, service and compliance.

Located just outside Boston, Massachusetts, HEAG is the premier Title IV Student Financial Aid compliance and technology consulting firm. We provide holistic solutions that help colleges optimize technology and business processes so they can successfully support their students.

We specialize in compliance with Title IV rules and regulations and have successfully provided operational guidance and support to the higher education community for well over 30 years. We pride ourselves on compliance expertise and our ability to adapt to an ever-changing industry. By staying abreast of regulatory changes and new technology solutions, HEAG is a consistent resource for public and private institutions of all sizes and types across the country.

Learn more about the launch of ReggieAI by contacting HEAG’s Vice President of Compliance & Quality Assurance at kwrightmoore@heag.us.

Request or inquire about HEAG services at info@heag.us.

Visit us at www.heag.us.

Media Contact
Melissa Maichle, Higher Education Assistance Group, 1 7815348620, melmaichle@gmail.com, https://heag.us/ 

 

View original content to download multimedia:https://www.prweb.com/releases/heag-launches-innovative-ai-tool-to-assist-financial-aid-professionals-302331947.html

SOURCE Higher Education Assistance Group

Continue Reading

Technology

Waystar Reports Third Quarter 2026 Results

Published

on

By

Q3 revenue of $325.6M, up 21% year over year

Q3 net income of $31.0M and non-GAAP net income of $87.1M

Q3 net income margin of 10%; adjusted EBITDA margin of 43%

LEHI, Utah and LOUISVILLE, Ky., Nov. 2, 2026 /PRNewswire/ — Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the third quarter ended September 30, 2026.

“Waystar delivered another quarter of robust bookings and healthy demand across the business,” said Matt Hawkins, Chief Executive Officer of Waystar. “Providers are increasingly consolidating more of the revenue cycle onto Waystar’s connected platform, deepening relationships across both new and existing clients as they adopt more of our AI-powered capabilities. We are focused on executing against the opportunities in front of us and extending our market leadership as we leverage AI and agentic capabilities to reshape the revenue cycle.”

Third Quarter 2026 Financial Highlights

Revenue of $325.6 million, up 21% year-over-yearNet income of $31.0 million, GAAP net income per diluted share of $0.16, and net income margin of 10%Non-GAAP net income of $87.1 million and non-GAAP net income per diluted share of $0.44Adjusted EBITDA of $139.3 million and adjusted EBITDA margin of 43%Cash flow from operations of $103.9 million and unlevered free cash flow of $114.8 million

Key Performance Metrics and Revenue Disaggregation

1,488 clients contributed over $100,000 in LTM revenue, up 14% year-over-yearNet revenue retention rate (NRR) of 108%Third quarter 2026 subscription revenue of $180.7 million, up 34% year-over-yearThird quarter 2026 volume-based revenue of $142.9 million, up 8% year-over-yearThird quarter 2026 provider revenue of $243.4 million, up 28% year-over-yearThird quarter 2026 patient revenue of $82.2 million, up 5% year-over-year

Financial Outlook

As of November 2, 2026, Waystar provides the following guidance for its full fiscal year 2026.1

Total revenue is expected to be between $1.277 billion and $1.287 billionAdjusted EBITDA is expected to be between $543 million and $549 millionNon-GAAP net income is expected to be between $322 million and $337 millionDiluted non-GAAP net income per share is expected to be between $1.63 and $1.71

Webcast Information

Waystar will discuss its financial results on a conference call scheduled at 4:30 p.m. Eastern Time today, November 2, 2026. A live audio conference call will be available on Waystar’s website at https://investors.waystar.com/news-events/events. Waystar will archive the webcast on its site for those unable to listen in real time. This earnings release and the related Current Report on Form 8-K, furnished November 2, 2026, are available on the Investor Relations page of Waystar’s website. We routinely post important information on our website, including corporate and investor presentations and financial information. We intend to use our website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included in the Investor Relations section of our website. Accordingly, investors should monitor this portion of our website, in addition to following our press releases, U.S. Securities and Exchange Commission (“SEC”) filings, and public conference calls and webcasts.

Non-GAAP Financial Measures

To supplement the consolidated financial statements prepared and presented in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release contains certain non-GAAP financial measures as defined below. We present non-GAAP financial measures as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. We believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate, and capital investments. Management uses adjusted EBITDA and adjusted EBITDA margin to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures. Management uses non-GAAP net income and non-GAAP net income per share to evaluate our core operating profitability on an after-tax basis exclusive of certain non-cash and non-recurring items that Management does not believe are indicative of our core operating performance, and to facilitate comparison with peer companies that may have different capital structures, acquisition histories, or tax profiles. Management uses non-GAAP operating expenses to evaluate trends in our cost structure excluding the items above. Management uses unlevered free cash flow to evaluate cash generation from our core business operations independent of our capital structure. Management uses net debt, gross debt, adjusted net leverage ratio and adjusted gross leverage ratio to evaluate our capital structure and leverage. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide.

Adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income, non-GAAP net income per share, non-GAAP operating expenses, unlevered free cash flow, net debt, gross debt, adjusted net leverage ratio and adjusted gross leverage ratio are not recognized terms under GAAP and should not be considered as an alternative to net income (loss), net income (loss) margin or the related GAAP expense line items as measures of financial performance, cash provided by operating activities as a measure of liquidity, total debt as a measure of indebtedness, or any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use, as they do not consider certain cash requirements such as interest payments, tax payments, and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. A reconciliation is provided below for our non-GAAP financial measures to the most directly comparable financial measure stated in accordance with GAAP. A quantitative reconciliation of the forward-looking non-GAAP financial measures included in our financial outlook is not provided for the reasons described under “Financial Outlook.” Investors are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

The following non-GAAP financial measures and key performance metrics are defined below:

Adjusted EBITDA and adjusted EBITDA Margin

We define adjusted EBITDA as net income / (loss) before interest expense, net, income tax expense / (benefit), depreciation and amortization, and as further adjusted for stock-based compensation expense, acquisition, integration and transaction costs, asset and lease impairments, costs related to amended debt agreements, IPO and secondary offering costs and costs related to other unusual, non-recurring or otherwise notable items. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

Non-GAAP Net Income and Non-GAAP Net Income Per Share

We define non-GAAP net income as GAAP net income excluding the impact of stock-based compensation, acquisition, integration and transaction costs, asset and lease impairments, costs related to our IPO, and the Secondary Offerings, costs related to amended debt agreements and amortization of intangibles, and costs related to other unusual, non-recurring or otherwise notable items. The tax effects of the adjustments are calculated using a management estimated annual effective non-GAAP tax rate of 21%, which is based on our statutory federal tax rate and provides consistency across interim reporting periods by eliminating the effects of non-recurring and period-specific items. Due to the differences in the tax treatment of items excluded from non-GAAP net income, our estimated tax rate on non-GAAP net income may differ from our GAAP tax rate. Non-GAAP net income per share is shown on both a basic and diluted basis and is defined as non-GAAP net income divided by the basic or diluted weighted-average shares, respectively.

Unlevered Free Cash Flow

We define unlevered free cash flow as cash from operations plus cash interest paid less capital expenses.

Net Debt

We define net debt as the sum of the current portion of long-term debt, long-term debt, and accounts receivable securitization less cash and equivalents and investment securities.

Adjusted Net Leverage Ratio

We define adjusted net leverage ratio as net debt divided by adjusted EBITDA over the preceding twelve months.

Gross Debt

We define gross debt as the sum of the current portion of long-term debt, long-term debt, and accounts receivable securitization.

Adjusted Gross Leverage Ratio

We define adjusted gross leverage ratio as gross debt divided by adjusted EBITDA over the preceding twelve months.

Key Performance Metrics

Net Revenue Retention Rate

Our Net Revenue Retention Rate compares twelve months of client invoices for our solutions at two period end dates. To calculate our Net Revenue Retention Rate, we first accumulate the total amount invoiced during the twelve months ending with the prior period-end or Prior Period Invoices. We then calculate the total amount invoiced to those same clients for the twelve months ending with the current period-end, or Current Period Invoices. Current Period Invoices are inclusive of upsell, downsell, pricing changes, clients that cancel or chose not to renew, and discontinued solutions with continuing clients. The Net Revenue Retention Rate is then calculated by dividing the Current Period Invoices by the Prior Period Invoices. Our total invoices included in the analysis are greater than 98% of reported revenue. We use Net Revenue Retention Rate to evaluate our ongoing operations and for internal planning and forecasting purposes. Acquired businesses are included in the last-twelve-month Net Revenue Retention Rate in the ninth quarter after acquisition, which is the earliest point that comparable post-acquisition invoices are available for both the current and prior twelve-month period.

Customer Count with >$100,000 of Revenue

We regularly monitor and review our count of clients who generate more than $100,000 of revenue.

Our count of clients who generate more than $100,000 of revenue is based on an accumulation of the amounts invoiced to clients over the preceding twelve months. The invoices for acquired clients are included starting in the first full calendar quarter after the date of acquisition.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, statements regarding Waystar’s expectations relating to future operating results and financial position, including full year 2026, and future periods; the performance of our new product offerings; our industry and market opportunities, business strategy, goals, and expectations concerning our market position, future operations, margins and profitability, capital expenditures, liquidity, and capital resources and other financial and operating information. Forward-looking statements include all statements that are not historical facts. These statements may include words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” “outlook,” the negative version of these words or similar terms and phrases to identify forward-looking statements in this press release, including the discussion of outlook for full fiscal year 2026.

The forward-looking statements contained in this press release are based on management’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. The following factors are among those that may cause actual results to differ materially from the forward-looking statements: our operation in a highly competitive industry; our ability to retain our existing clients and attract new clients; our ability to successfully execute on our business strategies in order to grow; our ability to accurately assess the risks related to acquisitions and successfully integrate acquired businesses, including the acquisition of Iodine; our ability to establish and maintain strategic relationships; the growth and success of our clients and overall healthcare transaction volumes; consolidation in the healthcare industry; our selling cycle of variable length to secure new client agreements; our implementation cycle that is dependent on our clients’ timing and resources; our dependence on our senior management team and certain key employees, and our ability to attract and retain highly skilled employees; the accuracy of the estimates and assumptions we use to determine the size of our total addressable market; our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes or evolving industry standards; the interoperability, connectivity, and integration of our solutions with our clients’ and their vendors’ networks and infrastructures; the performance and reliability of internet, mobile, and other infrastructure; the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions; our reliance on certain third-party vendors and providers; any errors or malfunctions in our products and solutions; failure by our clients to obtain proper permissions or provide us with accurate and appropriate information; the potential for embezzlement, identity theft, or other similar illegal behavior by our employees or vendors, and a failure of our employees or vendors to observe quality standards or adhere to environmental, social, and governance standards; our compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks; increases in card network fees and other changes to fee arrangements; the effect of payer and provider conduct which we cannot control; privacy concerns and security breaches or incidents relating to our platform or data (including personal information and other regulated data); the complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity; our ability to adequately protect and enforce our intellectual property rights; our ability to use or license data and integrate third-party technologies; the development, deployment, and use of AI; our use of “open source” software; legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights; claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties; the heavily regulated industry in which we conduct business; the uncertain and evolving healthcare regulatory and political framework; healthcare laws and data privacy and security laws and regulations governing our Processing of personal information (which may also be referred to as “personal data” or “personally identifiable information”); reduced revenues in response to changes to the healthcare regulatory landscape; legal, regulatory, and other proceedings that could result in adverse outcomes; contractual obligations requiring compliance with certain provisions of the Bank Secrecy Act/anti-money laundering laws and regulations; existing laws that regulate our ability to engage in certain marketing activities; our full compliance with website accessibility standards; any changes in our tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities; limitations on our ability to use our net operating losses to offset future taxable income; losses due to asset impairment charges; our substantial debt and restrictive covenants in the agreements governing our Credit Facilities; interest rate fluctuations; unavailability of additional capital on acceptable terms or at all; the impact of general macroeconomic conditions; our history of net losses and our ability to achieve or maintain profitability; the interests of certain investors may be different than the interests of other holders of our securities; and each of the other factors discussed under the heading of “Risk Factors” in the Company’s 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 17, 2026, and in other reports filed with the SEC, all of which are available on the Investor Relations page of our website at investors.waystar.com.

Any forward-looking statements made by us in this press release speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.

About Waystar

Waystar’s mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing approximately 1.5 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar’s enterprise-grade platform annually processes over 8.5 billion healthcare payment transactions, including over $3.0 trillion in annual gross claims and spanning approximately 60% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

1We have not reconciled the forward-looking adjusted EBITDA, non-GAAP net income, and non-GAAP net income per share guidance included above to the most directly comparable GAAP measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, and certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

Waystar Holding Corp.

Unaudited Consolidated Statements of Operations

(in thousands, except for share and per share data)

Three months ended
September 30,

Nine months ended
September 30,

2026

2025

2026

2025

Revenue

$    325,624

$     268,651

$     959,172

$    795,740

Operating expenses

Cost of revenue (exclusive of
depreciation and amortization expenses)

99,202

85,136

293,923

255,525

Sales and marketing

51,998

45,158

148,207

128,805

General and administrative

51,393

32,422

118,495

84,914

Research and development

20,299

12,403

56,390

36,103

Depreciation and amortization

41,466

33,300

124,384

100,106

      Total operating expenses

264,358

208,419

741,399

605,453

Income from operations

61,266

60,232

217,773

190,287

Other expense

Interest expense, net

(18,182)

(16,613)

(56,531)

(52,195)

Related party interest expense

(1,115)

(902)

(3,059)

(2,475)

Income before income taxes

41,969

42,717

158,183

135,617

Income tax expense

10,944

12,069

43,008

43,516

Net income

$       31,025

$     30,648

$      115,175

$       92,101

Net income per share:

   Basic

0.16

0.18

0.60

0.53

   Diluted

0.16

0.17

0.59

0.51

Weighted-average shares outstanding:

   Basic

191,938,402

174,352,079

191,825,646

173,388,077

   Diluted

195,913,142

181,240,033

195,743,104

181,165,738

 

Waystar Holding Corp.

Unaudited Consolidated Balance Sheets

(in thousands, except for share and per share data)

September 30,
2026

December 31,
2025

Assets

Current assets

  Cash and cash equivalents

$            30,820

$            61,355

    Restricted cash

24,161

15,454

    Investment securities

246,075

24,877

  Accounts receivable, net of allowance of $4,130 at
  September 30, 2026 and $6,170 at December 31, 2025

187,007

177,037

  Income tax receivable

—

6,437

  Prepaid expenses

22,834

20,078

  Other current assets

4,551

3,174

    Total current assets

515,448

308,412

    Property, plant and equipment, net

73,172

51,649

    Operating lease right-of-use assets, net

11,922

12,972

    Intangible assets, net

1,189,418

1,292,839

    Goodwill

4,014,868

4,016,818

  Deferred costs

110,720

93,951

  Other long-term assets

7,292

8,459

   Total assets

$         5,922,840

$         5,785,100

Liabilities and stockholders’ equity

Current liabilities

    Accounts payable

$            68,078

$           50,949

    Accrued compensation

31,025

40,942

    Aggregated funds payable

23,369

15,104

    Other accrued expenses

38,020

22,990

    Deferred revenue

64,773

67,855

    Current portion of long-term debt

13,404

13,537

    Related party current portion of long-term debt

790

657

    Current portion of operating lease liabilities

5,713

6,029

    Total current liabilities

245,172

218,063

Long-term liabilities

    Deferred tax liability

174,539

211,320

    Long-term debt, net, less current portion

1,374,057

1,394,523

    Related party long-term debt, net, less current portion

75,468

64,186

    Operating lease liabilities, net of current portion

11,163

11,994

    Deferred revenue – long-term

5,572

5,496

    Other long-term liabilities

278

692

   Total liabilities

1,886,249

1,906,274

Commitments and contingencies (Note 20)

Stockholders’ equity

Preferred stock $0.01 par value – 100,000,000 shares authorized as of September 30, 2026
 and December 31, 2025, respectively; zero shares issued or outstanding as of
 September 30, 2026 and December 31, 2025, respectively

—

—

Common stock $0.01 par value – 2,500,000,000 shares authorized at September 30, 2026
 and December 31, 2025, respectively; 193,813,805 and 191,587,193 shares outstanding at
 September 30, 2026 and December 31, 2025, respectively; 192,265,522 and 191,587,193
 shares outstanding at September 30, 2026 and December 31, 2025, respectively

1,938

1,916

Treasury stock, at cost

(33,487)

—

Additional paid-in capital

4,060,817

3,986,353

Accumulated other comprehensive income (loss)

959

(632)

Retained earnings (accumulated deficit)

6,364

(108,811)

 Total stockholders’ equity

4,036,591

3,878,826

 Total liabilities and stockholders’ equity

$         5,922,840

$         5,785,100

 

Waystar

Unaudited Consolidated Statements of Cash Flows

(in thousands)

Nine Months Ended September 30,

2026

2025

Cash flows from operating activities

Net income

$           115,175

$            92,101

Adjustments to reconcile net income to net cash provided by operating activities

Depreciation and amortization

124,384

100,106

Stock-based compensation

49,691

29,871

Provision for bad debt expense

2,884

2,605

Loss on extinguishment of debt

113

711

Impairment expense

1,990

—

Deferred income taxes

(37,490)

22,959

Amortization of debt discount and issuance costs

2,010

2,021

Other

86

—

Changes in:

Accounts receivable

(12,854)

(3,045)

Income tax receivable

6,437

2,838

Prepaid expenses and other current assets

(4,898)

(4,980)

Deferred costs

(16,282)

(7,116)

Other long-term assets

705

(2,362)

Accounts payable and accrued expenses

20,824

10,580

Deferred revenue

(3,006)

(1,863)

Operating lease right-of-use assets and lease liabilities

(1,582)

(1,387)

Net cash provided by operating activities

248,187

243,039

Cash flows from investing activities

 Purchase of property and equipment and capitalization of internally developed software costs

(41,359)

(17,069)

 Purchase of investment securities

(368,341)

(206,444)

 Proceeds from sale or maturity of investment securities

149,088

206,444

 Measurement period adjustments related to prior year acquisition

2,037

—

Net cash used in investing activities

(258,575)

(17,069)

Cash flows from financing activities

 Change in aggregated funds liability

8,265

1,789

 Repurchase of common stock

(33,487)

—

 Proceeds from issuance of common stock from employee equity plans

24,628

22,439

 Proceeds from issuances of debt, net of creditor fees

19,800

—

 Payments on debt

(30,646)

(8,751)

 Finance lease liabilities paid

—

(672)

Net cash provided by (used in) financing activities

(11,440)

14,805

  Increase/(decrease) in cash and cash equivalents during the period

(21,828)

240,775

  Cash and cash equivalents and restricted cash–beginning of period

76,809

204,582

  Cash and cash equivalents and restricted cash–end of period

$           54,981

$          445,357

Supplemental disclosures of cash flow information

  Interest paid

$           62,124

$           59,303

  Cash taxes paid (refunds received), net

58,882

9,439

Non-cash investing and financing activities

  Fixed asset purchases in accounts payable

996

539

Reconciliation of Balance Sheet Cash Accounts to Cash Flow Statement

Balance sheet

  Cash and cash equivalents

30,820

421,056

  Restricted cash

24,161

24,301

  Total

54,981

445,357

 

Waystar

Reconciliation of Adjusted EBITDA

 (in thousands)

(unaudited)

Three months ended
September 30,

Nine months ended
September 30,

($ in thousands)

2026

2025

2026

2025

Net income

$  31,025

$ 30,648

$  115,175

$   92,101

Interest expense, net

19,297

17,515

59,590

54,670

Income tax expense

10,944

12,069

43,008

43,516

Depreciation and amortization

41,466

33,300

124,384

100,106

Stock-based compensation expense

24,442

11,597

49,691

29,871

Acquisition, integration and transaction costs

9,629

5,313

13,236

6,197

Asset and lease impairments

—

—

1,990

—

Other (a)

2,499

2,261

4,356

6,540

Adjusted EBITDA

$ 139,302

$ 112,703

$ 411,430

$ 333,001

Revenue

$ 325,624

$ 268,651

$ 959,172

$ 795,740

Net income margin

9.5 %

11.4 %

12.0 %

11.6 %

Adjusted EBITDA margin

42.8 %

42.0 %

42.9 %

41.8 %

(a)

For the three and nine months ended September 30, 2026, adjustments reflect costs associated with a cybersecurity incident (see Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026) totaling $1.4 million and $3.0 million, respectively and executive severance totaling $1.1 million and $1.1 million, respectively. For the three and nine months ended September 30, 2025, adjustments include secondary offering costs of $1.4 million and $4.6 million, respectively; costs related to amended debt agreements totaling $0.6 million; lease-related costs associated with the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance costs totaling $0.0 million and $0.6 million, respectively.

 

Waystar

Reconciliation of Non-GAAP Operating Expenses

(in thousands)

(unaudited)

Three months ended
September 30,

Nine months ended
September 30,

2026

2025

2026

2025

Cost of revenue (exclusive of depreciation and amortization expenses)

$       99,202

$       85,136

$      293,923

$      255,525

Less Stock-based compensation expense

(1,072)

(418)

(2,101)

(1,064)

Less Acquisition, integration and transaction costs

(1,011)

(3)

(3,266)

(3)

Less Other (a)

(2)

–

(2)

–

Cost of revenue (exclusive of depreciation and amortization expenses), adjusted

$        97,117

$       84,715

$     288,554

$     254,458

Sales and marketing

51,998

45,158

148,207

128,805

Add/(Less) Stock-based compensation expense

(2,520)

(2,392)

(4,867)

(6,198)

Add/(Less) Acquisition, integration and transaction costs

–

(79)

54

(79)

Less Other (a)

(146)

–

(246)

–

Sales and marketing, adjusted

$       49,332

$       42,687

$      143,148

$      122,528

General and administrative

51,393

32,422

118,495

84,914

Less Stock-based compensation expense

(18,182)

(7,218)

(36,499)

(18,418)

Less Acquisition, integration and transaction costs

(7,681)

(5,119)

(8,878)

(5,778)

Less Asset and lease impairments

–

–

(1,990)

–

Less Other (a)

(2,347)

(2,261)

(4,104)

(6,540)

General and administrative, adjusted

$        23,183

$       17,824

$       67,024

$       54,178

Research and development

20,299

12,403

56,390

36,103

Less Stock-based compensation expense

(2,668)

(1,569)

(6,224)

(4,191)

Less Acquisition, integration and transaction costs

(937)

(112)

(1,146)

(337)

Less Other (a)

(4)

–

(4)

–

Research and development, adjusted

$       16,690

$       10,722

$       49,016

$        31,575

Depreciation and amortization

41,466

33,300

124,384

100,106

Less Intangible amortization

(34,474)

(27,851)

(103,421)

(84,081)

Depreciation and amortization, adjusted

$        6,992

$        5,449

$       20,963

$       16,025

Income tax expense

10,944

12,069

43,008

43,516

Plus Tax effect of adjustments

14,919

9,875

36,266

26,605

Income tax expense, adjusted

$       25,863

$       21,944

$       79,274

$        70,121

(a)

For the three and nine months ended September 30, 2026, adjustments reflect costs associated with a cybersecurity incident (see Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026) totaling $1.4 million and $3.0 million, respectively, and executive severance totaling $1.1 million and $1.1 million, respectively. For the three and nine months ended September 30, 2025, adjustments include secondary offering costs of $1.4 million and $4.6 million, respectively; costs related to amended debt agreements totaling $0.6 million; lease-related costs associated with the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance costs totaling $0.0 million and $0.6 million, respectively.

 

Waystar

 Reconciliation of Non-GAAP Net Income

(in thousands, except share and per share amounts)

(unaudited)

Three months ended
September 30,

Nine months ended
September 30,

($ in thousands)

2026

2025

2026

2025

Net income

$       31,025

$      30,648

$       115,175

$        92,101

Stock-based compensation

24,442

11,597

49,691

29,871

Acquisition, integration and transaction costs

9,629

5,313

13,236

6,197

Asset and lease impairments

—

—

1,990

—

Other (a)

2,499

2,261

4,356

6,540

Intangible amortization

34,474

27,851

103,421

84,081

Tax effect of adjustments

(14,919)

(9,875)

(36,266)

(26,605)

Non-GAAP net income

$       87,150

$      67,795

$     251,603

$      192,185

Non-GAAP net income per share:

Basic

$           0.45

$          0.39

$           1.31

$            1.11

Diluted

$           0.44

$          0.37

$           1.29

$            1.06

Weighted-average shares outstanding:

Basic

191,938,402

174,352,079

191,825,646

173,388,077

Diluted

195,913,142

181,240,033

195,743,104

181,165,738

(a)

For the three and nine months ended September 30, 2026, adjustments reflect costs associated with a cybersecurity incident (see Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026) totaling $1.4 million and $3.0 million, respectively, and executive severance totaling $1.1 million and $1.1 million, respectively. For the three and nine months ended September 30, 2025, adjustments include secondary offering costs of $1.4 million and $4.6 million, respectively; costs related to amended debt agreements totaling $0.6 million; lease-related costs associated with the relocation of our Louisville office totaling $0.2 million and $0.7 million, respectively, and executive severance costs totaling $0.0 million and $0.6 million, respectively.

 

Waystar

Reconciliation of Unlevered Free Cash Flow

(in thousands)

(unaudited)

Three months ended
September 30,

Nine months ended
September 30,

2026

2025

2026

2025

Net cash provided by operating activities

$  103,863

$   82,030

$  248,187

$ 243,039

Interest paid

20,834

19,558

62,124

59,303

Purchase of PP&E and capitalization of internally developed software costs

(9,919)

(5,876)

(41,359)

(17,069)

Unlevered free cash flow

$   114,778

$    95,712

$  268,952

$  285,273

 

Waystar

Reconciliation of Net Debt

 (in thousands)

(unaudited)

September 30,

2026

2025

First lien term loan facility outstanding debt, current

$          14,194

$          11,668

First lien term loan facility outstanding debt, net of current portion

1,356,407

1,143,127

Receivables facility outstanding debt

100,000

80,000

Cash and cash equivalents

(30,820)

(421,056)

Investment securities

(246,075)

–

Net debt

$     1,193,706

$       813,739

Trailing Twelve Months Adjusted EBITDA

$        540,575

$       433,154

Adjusted gross leverage ratio

2.7x

2.9x

Adjusted net leverage ratio

2.2x

1.9x

 

Waystar

Reconciliation of Trailing Twelve Months (TTM) Adjusted EBITDA

(in thousands)

(unaudited)

Three Months Ended

TTM

September 30,
2026

June 30,
2026

March 31,
2026

December 31,
2025

September 30,
2026

Net income

$         31,025

$      40,867

$      43,283

$          19,988

$        135,163

Interest expense, net

19,297

19,646

20,647

22,872

82,462

Income tax expense

10,944

15,529

16,535

16,158

59,166

Depreciation and amortization

41,466

41,466

41,452

40,442

164,826

Stock-based compensation expense

24,442

13,803

11,446

12,198

61,889

Acquisition, integration and transaction costs

9,629

1,801

1,806

14,877

28,113

Asset and lease impairments

–

1,990

–

–

1,990

Other (a)

2,499

1,623

234

2,610

6,966

Adjusted EBITDA

$      139,302

$    136,725

$    135,403

$        129,145

$       540,575

(a) Adjustments reflect costs associated with a cybersecurity incident (see Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026), costs related to amended debt agreements, secondary offering expenses, executive severance and lease-related costs associated with the relocation of our Louisville office.

Media Contact
Kristin Lee
kristin.lee@waystar.com

Investor Contact
Edward Parker
investors@waystar.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/waystar-reports-third-quarter-2026-results-302926866.html

SOURCE Waystar

Continue Reading

Technology

RADIANT LOGISTICS TO HOST INVESTOR CALL TO DISCUSS FINANCIAL RESULTS FOR FIRST FISCAL QUARTER ENDED SEPTEMBER 30, 2026

Published

on

By

Call Scheduled for Monday, November 9, at 4:30 PM Eastern

RENTON, Wash., Nov. 2, 2026 /PRNewswire/ — Radiant Logistics, Inc. (NYSE American: RLGT), a technology-enabled global transportation and value-added logistics services company, will host a conference call on Monday, November 9, 2026 at 4:30 PM Eastern to discuss the Company’s financial results for the three months ended September 30, 2026.

The conference call is open to all interested parties, including individual investors and press.  Bohn Crain, Founder and CEO will host the call.

Conference Call Details

Date/Time:       Monday, November 9, 2026 at 4:30 PM Eastern

DIAL-IN:          US (888) 506-0062; Intl. (973) 528-0011
                        Participant Access Code: 278998

REPLAY:         November 10, 2026 at 9:30 AM Eastern to November 23, 2026 at 4:30 PM Eastern
                        US (877) 481-4010; Intl. (919) 882-2331
                        Replay ID number: 54749

Webcast Details
This call is also being webcast and may be accessed via Radiant’s web site at www.radiantdelivers.com or at https://www.webcaster5.com/Webcast/Page/2191/54749.

About Radiant Logistics (NYSE American: RLGT)
Radiant Logistics, Inc. (www.radiantdelivers.com) operates as a third-party logistics company, providing technology-enabled global transportation and value-added logistics services primarily to customers in the United States and Canada. Through its comprehensive service officering, Radiant provides domestic and international freight forwarding along with truck and rail brokerage services to a diversified account base including manufactures, distributors and retailers, which it supports from an extensive network of company and agent-owned offices throughout North America and other key markets around the world. Radiant’s value-added logistics services include warehouse and distribution, customs brokerage, order fulfillment, inventory management and technology services.

View original content to download multimedia:https://www.prnewswire.com/news-releases/radiant-logistics-to-host-investor-call-to-discuss-financial-results-for-first-fiscal-quarter-ended-september-30-2026-302926855.html

SOURCE Radiant Logistics, Inc.

Continue Reading

Technology

ADC Therapeutics Announces New Employee Inducement Grant

Published

on

By

LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company’s common shares to a new employee on November 2, 2026. (“Grant”).

The Grant was offered as material inducement to the employee’s employment. The Grant was approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grant was made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grant shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).

ADC Therapeutics’ CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: whether Tanabe’s marketing authorization application filed with Japan’s Ministry of Health for ZYNLONTA will be accepted, the timing and potential approval of the marketing authorization application for ZYNLONTA in Japan, the timing and payment of future regulatory and commercial milestones related to Japan, Nippon Shinyaku ability to successfully commercialize ZYNLONTA in Japan and the amount of future revenue in Japan and related payments to ADCT; the adequacy of the LOTIS-5 clinical trial data to support full regulatory approval and our ability to maintain accelerated approval in the United States and foreign jurisdictions for our product; our ability to identify and execute on potential regulatory and compendia pathways; the timing, content and outcome of meetings with and feedback or other communications provided by regulatory authorities including U.S. FDA including our ability to adequately address the serious concerns related to the LOTIS-5 trial results raised by the FDA at the recent pre-sBLA submission meeting; the timing, submission and outcome of an sBLA related to LOTIS-5 and potential approval; the actual and perceived benefit-risk profile for ZYNLONTA as studied in the LOTIS-5 trial; the assessment of the data from LOTIS-5 study, including additional analyses of outcomes observed for safety, efficacy and within key geographic regions and across certain patient sub-populations; the path for full regulatory approval for ZYNLONTA in the United States and foreign jurisdictions and into earlier lines of therapy; whether future LOTIS-7 results will be consistent with or different from the prior disclosure, the timing, results and publication of the full LOTIS-7 trial data and potential compendia inclusion; future regulatory strategy for a Phase 3 trial for the combination of ZYNLONTA plus glofitamab; our expected revenue growth in 2027 and the Company’s ability to sustain or grow ZYNLONTA® revenue in the future; our expected cash runway into 2029; changes in our regulatory and commercial strategy; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain or maintain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company’s clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities; uncertainties related to a potential change in domicile from Switzerland to Delaware, including the outcome of tax analyses associated with such redomiciliation, the receipt of requisite shareholder approval, and the ability to complete the redomiciliation on the anticipated terms and timeline, if at all; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-new-employee-inducement-grant-302925153.html

SOURCE ADC Therapeutics SA

Continue Reading

Trending